Schedule 13D ownership disclosure
CLEARSIDE BIOMEDICAL INC
Common Stock, $0.001 Par Value · CUSIP: 185063104
Event date: 2024-09-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Hatteras Venture Advisors IV SBIC, LLCReported CIK 0001675236
Shares: 0.00 · Class: 0%
- Hatteras Venture Partners IV SBIC, LP
Shares: 0.00 · Class: 0%
- Hatteras Venture Advisors IV, LLC
Shares: 0.00 · Class: 0%
- Hatteras Venture Partners IV, LP
Shares: 0.00 · Class: 0%
- Hatteras NC Fund, LP
Shares: 0.00 · Class: 0%
- John C. Crumpler
Shares: 125,793.00 · Class: 0.2%
- Robert A. Ingram
Shares: 130,881.00 · Class: 0.2%
- Kenneth B. Lee
Shares: 86,324.00 · Class: 0.1%
- Clay B. Thorp
Shares: 313,641.00 · Class: 0.4%
- Douglas Reed
Shares: 127,011.00 · Class: 0.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-016122
- Form type
- SCHEDULE 13D/A
- Filer
- Clearside Biomedical, Inc.
- CIK
- CIK 1539029
- Filed
- Feb 21, 2025
- Reporting period
- Sep 13, 2024
- Description
- Schedule 13D beneficial ownership